Tofogliflozin
- Generic Name
- Tofogliflozin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C22H26O6
- CAS Number
- 903565-83-3
- Unique Ingredient Identifier
- 554245W62T
- Background
Tofogliflozin has been used in trials studying the treatment and prevention of Diabetes Mellitus Type 2.
- Associated Conditions
- -
- Associated Therapies
- -
Effect of Tofogliflozin on UACR Compared to Metformin Hydrochloride in Diabetic Kidney Disease (TRUTH-DKD)
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-07-22
- Last Posted Date
- 2022-07-22
- Lead Sponsor
- Shinshu University
- Target Recruit Count
- 120
- Registration Number
- NCT05469659
- Locations
- 🇯🇵
Shinshu University, Matsumoto, Nagano, Japan
SGLT2 Inhibitor Versus Sulfonylurea on Type 2 Diabetes With NAFLD
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-01-07
- Last Posted Date
- 2021-07-02
- Lead Sponsor
- Kanazawa University
- Target Recruit Count
- 40
- Registration Number
- NCT02649465
- Locations
- 🇯🇵
Kanazawa University Graduate School of Medical Sciences, Kanazawa, Ishikawa, Japan
Tofogliflozin GLP-1 Analogue Combination Trial
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-09-02
- Last Posted Date
- 2020-11-17
- Lead Sponsor
- Kowa Company, Ltd.
- Target Recruit Count
- 65
- Registration Number
- NCT02537834
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath